- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00835094
A Randomized Trial Assessing Once Daily Administration of Mometasone Furoate DPI in Asthmatics (Study P02177)
February 7, 2022 updated by: Organon and Co
A Randomized Trial Assessing the Chronobiology of Once Daily Administration of Mometasone Furoate DPI in Patients With Asthma
This will be an open-label, randomized, parallel-group comparison of mometasone furoate dry powder inhaler (MF-DPI) 400 mcg once daily administered in the morning vs. the evening for 12 weeks in subjects with asthma.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
216
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects (and their parent/guardian if the subject is <18) must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent.
- Subjects must be >=12 years of age (unless restricted to an older age by local ethical committees or national health authorities), of either gender and any race.
- Subjects must have had a history of asthma for >=6 months.
If the subject is taking inhaled corticosteroids, the daily dose must be <= the upper limit defined below:
- budesonide <=800 mcg/day
- triamcinolone acetonide <=800 mcg/day
- beclomethasone dipropionate <=1000 mcg/day
- fluticasone propionate <=500 mcg/day
- flunisolide <=1000 mcg/day
- Women of childbearing potential must have a negative urine (hCG) pregnancy test on the day of randomization (Baseline visit).
- Women of childbearing potential (includes women who are <1 year postmenopausal) must be using an acceptable method of birth control (eg, hormonal contraceptive, medically prescribed IUD, condom in combination with spermicide) or be surgically sterilized (eg, hysterectomy or tubal ligation).
- Subjects must agree to inform their usual treating physician (if other than the study investigator) of their participation in this study.
Exclusion Criteria:
- Female subjects who are pregnant, breast-feeding, or are premenarcheal.
- Subjects who have required daily or alternate day oral corticosteroid treatment for more than a total of 14 days during the 6 months immediately prior to Visit 1, and/or subjects who have required a course of systemic corticosteroids within the previous month.
- Subjects who have had either an asthma exacerbation or a clinically relevant change in asthma medication within the last 4 weeks.
- Subjects who have been admitted to the hospital for asthma control within the previous 3 months or more than once within the previous 6 months.
- Subjects who have required ventilator support for respiratory failure secondary to their asthma within the last 5 years.
- Subjects who have used any investigational drug in the 30 days prior to Baseline, or subjects who have been treated with any investigational antibody for asthma in the 90 days prior to Baseline.
- Subjects who are allergic or have had an idiosyncratic reaction to corticosteroids.
- Subjects with any clinically significant disorder of the cardiovascular, neurologic, hematologic, gastrointestinal, cerebrovascular, or immunologic system, or respiratory disease other than asthma (eg, COPD), or any other disorder which may interfere with the study evaluations or affect subject safety.
- Subjects with a history of drug abuse, poor motivation, hypochondriasis, or any other emotional or intellectual problems that are likely to limit the validity of consent to participate in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Morning
|
MF-DPI 400 mcg once daily in the morning for 12 weeks
Other Names:
MF-DPI 400 mcg once daily in the evening for 12 weeks
Other Names:
|
Experimental: Evening
|
MF-DPI 400 mcg once daily in the morning for 12 weeks
Other Names:
MF-DPI 400 mcg once daily in the evening for 12 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Between-treatment group comparisons (MF-DPI 400 mcg once daily in the morning compared to the evening) of daytime and nocturnal symptoms based on a 4 point scale.
Time Frame: 12 weeks
|
12 weeks
|
To compare the incidence of adverse events of MF-DPI 400 mcg once daily administered in the morning compared to the evening.
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To assess morning vs. evening compliance with therapy.
Time Frame: 12 weeks
|
12 weeks
|
To assess subject satisfaction with the Twisthaler^TM device.
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2002
Primary Completion (Actual)
July 1, 2003
Study Completion (Actual)
July 1, 2003
Study Registration Dates
First Submitted
October 30, 2008
First Submitted That Met QC Criteria
February 2, 2009
First Posted (Estimate)
February 3, 2009
Study Record Updates
Last Update Posted (Actual)
February 17, 2022
Last Update Submitted That Met QC Criteria
February 7, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P02177
Plan for Individual participant data (IPD)
Study Data/Documents
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Universita di VeronaCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
-
Istanbul University - Cerrahpasa (IUC)CompletedAsthma | Asthma in Children | Asthma Attack | Asthma AcuteTurkey
Clinical Trials on Mometasone furoate
-
Teva Pharmaceuticals USACompletedSeasonal Allergic Rhinitis
-
Padagis LLCCompleted
-
Eurofarma Laboratorios S.A.CompletedMild to Moderate Persistent Allergic RhinitisBrazil
-
Massachusetts General HospitalMerck Sharp & Dohme LLC; Massachusetts Eye and Ear InfirmaryTerminatedNasal PolypsUnited States
-
Montefiore Medical CenterWithdrawnRadiation DermatitisUnited States
-
University of FloridaGlaxoSmithKline; Food and Drug Administration (FDA)CompletedHypersensitivityUnited States
-
GlaxoSmithKlineCompleted
-
Novartis PharmaceuticalsCompletedAsthmaGermany, Slovakia, Bulgaria, Canada, Poland, Korea, Republic of, Netherlands, Japan
-
Novartis PharmaceuticalsCompletedMild AsthmaGermany, India, Korea, Republic of, Poland, South Africa, Estonia, Italy, Russian Federation, Thailand, Latvia, Lithuania, Colombia, Hungary, Peru, Philippines, Slovakia, Bulgaria, Vietnam, Japan, Malaysia, Chile, Sweden
-
James J. Peters Veterans Affairs Medical CenterKessler Institute for RehabilitationUnknownSpinal Cord InjuryUnited States